SMC1A — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Selumetinib (SCHEMBL155456)	1.00	1/20
Selumetinib (SCHEMBL2354340)	0.94	1/20
SCHEMBL4546029	0.91	1/20
SCHEMBL4546010	0.87	1/20
SCHEMBL1038067	0.85	1/20
SCHEMBL4545997	0.85	1/20
SCHEMBL569289	0.84	1/20
Binimetinib (SCHEMBL570088)	0.84	1/20
SCHEMBL1037416	0.84	1/20
SCHEMBL4545993	0.83	1/20
SCHEMBL1077790	0.82	1/20
SCHEMBL2877129	0.82	1/20
SCHEMBL4546015	0.82	1/20
SCHEMBL4546033	0.82	1/20
SCHEMBL4546036	0.82	1/20
SCHEMBL14064334	0.82	1/20
SCHEMBL4546041	0.82	1/20
SCHEMBL1040194	0.81	1/20
SCHEMBL4546013	0.81	1/20
SCHEMBL4546042	0.81	1/20

Clinical trials — most relevant to SMC1A by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Cornelia De Lange Syndrome: Assessing Positive Effects of Lithium Treatment	PHASE2/PHASE3	RECRUITING
Low-Dose Danazol for the Treatment of Telomere Related Diseases	PHASE2	COMPLETED
Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma	PHASE1	UNKNOWN
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome	PHASE1	COMPLETED
Imetelstat for Children With Refractory or Recurrent Solid Tumors and Lymphoma	PHASE1	WITHDRAWN
Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load	PHASE1	COMPLETED
Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas	PHASE1	COMPLETED
Panobinostat and Epirubicin in Treating Patients With Metastatic Malignant Solid Tumors	PHASE1	COMPLETED
Immunophenotyping and Xist Gene in AML	nan	UNKNOWN
Mesenchymal Stem Cells in NPM1 Mutated Low Risk Acute Myeloid Leukemia: a Study of the Tumor Microenvironment and Its Contribution to the Outcome	nan	COMPLETED
Study of Synapsis and Recombination in Male Meiosis and the Implications in Infertility	nan	COMPLETED
Proteomic-Based Profiling of Lymphomas: Chromatin Proteomics; Composition and Modification of Histone and Non-Histone Chromosomal Proteins	nan	COMPLETED
Telomeres Length in Israeli Fibrotic ILD Patients	nan	ENROLLING_BY_INVITATION
Telomeric Abnormalities in Colorectal Diseases by Fluorescent in Situ Hybridization Technique	nan	UNKNOWN
Chromosome 18 Clinical Research Center	nan	RECRUITING
Genetic of SportS Induced Endofibrotic Remodeling	nan	COMPLETED
Impact of Weight Loss on the Human Sperm Epitranscriptome	nan	ACTIVE_NOT_RECRUITING
Biological Aging Hallmarks-Guided Integrative TCM and Conventional Medicine in Post-Treatment Unexplained Female Infertility	nan	RECRUITING
Collaborative Studies on the Genetics of Asthma (CSGA)	nan	COMPLETED
Nasal Brushing for the Diagnosis and Understanding of Telomeropathies	nan	UNKNOWN
A National Retrospective Population Based Cohort Study of the Natural History of Ataxia Telangiectasia	nan	UNKNOWN
Muscle Tissue Bank for Muscular Dystrophy	nan	COMPLETED
The Contribution of Optical Mapping to the Characterization of Chromosomal Rearrangements in Patients With Neurodevelopmental Disorders	nan	RECRUITING
Prenatal Cell-free DNA Screening in Pregnancies With Diverse Genetic Risk Profiles Utilizing Targeted and Whole-exome Sequencing	nan	NOT_YET_RECRUITING
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients	nan	RECRUITING
Turner Syndrome: Genotype and Phenotype	nan	COMPLETED
Genome-wide Single Cell Haplotyping as a Generic Method for Preimplantation Genetic Diagnosis	nan	UNKNOWN
Epigenetics in the Aging Process	nan	COMPLETED
Aerobic Exercise and Telomere Length in Patients With Heart Failure.	nan	UNKNOWN
DNA Methylation and Autoimmune Thyroid Diseases	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a SMC1A binder may also engage these)

Protein	Name	Similarity
O97593	—	1.000	O97593 →
Q9CU62	—	1.000	Q9CU62 →
O93308	—	1.000	O93308 →
Q9Z1M9	—	1.000	Q9Z1M9 →
SMC4	Structural maintenance of chromosomes protein 4	0.982	landscape →
Q8CG47	—	0.976	Q8CG47 →
Q56YN8	—	0.976	Q56YN8 →
Q805A1	—	0.975	Q805A1 →
Q802R9	—	0.973	Q802R9 →
P50532	—	0.972	P50532 →
E7F0W1	—	0.971	E7F0W1 →
Q9ERA5	—	0.969	Q9ERA5 →
Q8IY18	—	0.964	Q8IY18 →
Q8CG46	—	0.964	Q8CG46 →
Q8BKE9	—	0.963	Q8BKE9 →
EIF3A	Eukaryotic translation initiation factor 3 subunit A	0.961	landscape →
Q9LFS8	—	0.960	Q9LFS8 →
Q96LB3	—	0.959	Q96LB3 →
Q96MR6	—	0.958	Q96MR6 →
Q6PCR7	—	0.958	Q6PCR7 →
Q499U4	—	0.957	Q499U4 →
Q1JU68	—	0.957	Q1JU68 →
Q9CW03	—	0.956	Q9CW03 →
SMC3	Structural maintenance of chromosomes protein 3	0.956	landscape →
A2VD00	—	0.955	A2VD00 →
P23116	—	0.955	P23116 →
Q4A1L3	—	0.955	Q4A1L3 →
Q40554	—	0.955	Q40554 →
Q6P4T2	—	0.954	Q6P4T2 →
Q5ZLS3	—	0.954	Q5ZLS3 →